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PATIENTS AND METHODS
Thirty-five adult male and female outpatients were selected
from private practice for a 6-week study. Their ages
ranged from 19 to 68 years and 11 were males. With the
exception of 2 Asiatic patients, all were White. All had
bers of this class, sedative, hypnotic and anxiolytic pro-
perties.
In animals lorazepam has demonstrated anxiolytic and
anticonvulsant actions more potent than those of chlor-
diazepoxide,'-' and in human volunteers it has demonstrated
beneficial hypnotic' and amnesic' effects. In patients with
anxiety independent of, secondary to, or associated with,
disorders of the psyche or other functional disorders with-
out organic involvement. lorazepam has proved effective
and was well tolerated.'-"
The present open study was undertaken to evaluate the
anti-anxiety effects of lorazepam in non-confined patient
with anxiety states of diverse origins.
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size. The infundibulum probably acted as a special pul-
monary pump, according to Keith's' concept of the
functional significance of the bulbus cordis. These com-
pensatory mechanisms apparently prolonged life beyond
normal expectation in the light of the anatomical anom-
alies described.
SUMMARY
The efficacy of lorazepam, one of the newer benzodiaze-
pines, as an anxiolytic agent is assessed in a study in-
volving 35 non-hospitalised patients. No serious side-
effects were encountered and the drug, administered orally,
was well tolerated. The patients exhibited anxiety as a
primary symptom or in association with other disease
entities. The drug appeared to be most effective against
insomnia, tension and anxiety.
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agent as produces the conditions of anencephaly, etc., with
which lesions malformation of the bulbus is so often
associated.'
Finally one comes back to the problem of how efficient
pulmonary blood flow was maintained in this case for
survival during childhood and up to the age of 17 years.
The following possibilities can be postulated: that the
ductus arteriosus took a longer time to close during
infancy. thus allowing a period of aortic pulmonary
shunt. In the fetal heart there is normally a right ventri-
cular preponderance. The progressing hypertrophy of the
right ventricle must have played an important role in
forcing the blood through the ostium between the right
ventricle and infundibulum. One can also visualise a
gradual narrowing of this ostium as the heart grew in
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Lorazepam or 7-chloro-5-(O-chlorophenyl)-1.3-dihydro-3
hydroxy-2H-1. 4-benzodiazepin-2-one, is one of the newer
benzodiazepines. possessing in common with other mem-
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TABLE I. PSYCHIATRIC DIAGNOSIS
mild to severe anxiety as a primary symptom or in asso-
ciation with personality disorders, depression, phobias or
schizophrenia (Table I). Excluded from the study were
patients with known hypersensitivity to the test drug, or
with serious debiJitating organic disease, and pregnant
women. Generally lorazepam is not indicated in schizo-
phrenic patients, but in 2 schizophrenic patients in this series
the symptoms were of such intensity that the use of
lorazepam was considered an essential therapeutic
adjuvant.
The average daily oral dose of lorazepam varied from
1 mg to 9 mg, depending on the response and condition
of the patient. Most patients received from I mg to 3
mg of lorazepam daily. One patient required as much as
9.1 mg of lorazepam as an average daily dose, and 2
required as little as 1 mg daily. Where possible other
psychotropic medication was discontinued 2 weeks before
administration of lorazepam. Thirteen patients, however,
required antidepressant medication for varying periods
during the study.
Patient symptoms were evaluated and recorded on a
Hamilton Anxiety Rating Scale prior to therapy and at
weekly intervals thereafter for 6 weeks. Symptoms were


















and 3-severe, at the end of each week. Global evaluations
were rated independently of symptoms and recorded at the
end of each week using a 5-point scale: O--worse. I-no
change, 2-slightly improved, 3-moderately improved, and
4--much improved. Side-effects and investigator's com-
ments were also recorded. The data were then analysed
with appropriate statistical methodology to determine
significant pre- and post-treatment differences. A one-way
analysis of variance, adjusted for pretreatment differences
among patients. was performed on the individual items on
the Hamilton Anxiety Rating Scale and global evaluations
were chi-squared.
It should be noted that laboratory work-Ups and EEGs
would have been taken if required, but none were neces-
sary.
RESULTS AND DISCUSSION
All 35 patients completed 6 weeks of the study. The anti-
anxiety activity of lorazepam as reflected in the decline
of Hamilton scores for each week of therapy from pre-
treatment scores became apparent early in the study
(Table II). A one-way analysis of covariance_ with pre-
therapy scores as the covariant, further revealed that the
difference between weekly and pretherapy scores reached
significance at the 0,001 level. A chi-squared analysis of
the global ratings compared for changes over the 6-week
period also showed 'significant differences at the 0.001
level. A comparison of the global ratings of worse (0) and
no change (1), with those of slight (2), moderate (3) and
much improvement (4), showed that the percentage of
improvement for weeks 1, 2 and 3 were 43%, 83%, and
89%, respectively: for the remaining 3 weeks, collectively,
it was 94°{,.
Lorazepam se,emed most successful against insomnia,
tension, anxious mood, respiratory and general somatic
complaints, behaviour at interview and other tension- and
anxiety-linked symptoms. A subsequent chi-square analysis
of individual items on the Hamilton scale showed that
TABLE 11. RESPONSE TO LORAZEPAM
Hamilton anXiety rating scale changes· Improvement noted at week:
No. 3-2 3-1 3-0 2-1 2-0 1-0No change 1 2 3 4
Anxious mood 35 5 9 4 g 5 0 3 14 14 2 2
Tension 35 3 11 12 1 7 0 1 22 8 3 1
Fears 17 1 3 0 3 1 5 4 4 3 3 4
Insomnia 31 0 3 13 1 11 3 0 24 3 2 2
Intellectual 29 1 1 2 1 6 10 8 7 8 2 4
Depressed mood 30 2 0 2 1 8 7 10 5 5 5 5
General somatic 35 1 5 5 4 10 8 2 18 8 3 4
Cardiovascular 28 0 2 0 0 13 10 3 10 10 5 0
Respiratory 29 1 1 1 2 9 13 2 8 15 4 0
Gastro-intestinal 27 2 2 1 3 6 10 3 9 9 4 2
Genito-urinary 23 1 2 0 5 2 3 10 5 3 2 3
Behaviour at inter-
view 34 4 5 4' 5 15 0 14 16 3
·3-severe; 2-moderate; l-mild; O--absent.
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these symptoms had improved measurably from pre;
therapy ratings, reaching sign ificance at the 0,001 level
(Table Ill).
TABLE Ill. ORDER OF IMPROVEMENT
'Veeks
1 2 3 4 x' (3)
Anxious mood 14 14 2 2 18,00'
Tension 22 8 3 1 31,65'
Fo:ars 4 3 3 4 0,29
Insomnia 24 3 3 2 42,75'
Intellectual 7 8 2 4 4,33
Depressed mood 5 4 5 5 0,16
General somatic 18 8 3 4 17,06'
Cardiovascular 10 10 5 0 11,OOt
Respiratory 8 15 4 0 17,81'
Gastro-intestinal 9 9 4 2 6,33
Genito-urinary 5 3 2 3 1,46
Behaviour at interview 14 16 1 3 20,35'
1'<.:0.001
r 1'<0.01
Lorazepam exerted its greatest effect against insomnia,
tension and anxiety, in that order. Complete alleviation or
reduction in severity of symptoms was noted within the
first 2 weeks of treatment in approximately 80°(, of patients
(Table II). This included 16 patients with severe, 12 with
moderate, and 3 with mild degrees of insomnia; 26 patients
with severe and 8 with moderate degrees of tension, and
18 with severe and 14 with moderate symptoms of anxiety.
Patients who had previously experienced difficulty in
sleeping indicated that the medication had helped them
and that sleep was easily induced and well-sustained. It
appeared that lorazepam dispelled the anxiety and tension
which were probably responsible for the insomnia, and
its effect (in my opinion) exceeded all other benzodiaze-
pines as a sleep-inducer.
Fears. intellectual. gastro-intestinal and genito-urinary
symptoms as well as those relating to depressed mood,
were not significantly affected by the medication (Table
Ill).
Lorazepam exerted its least effect on depressed mood,
and only in those instances where the depressive states
were secondary to anxiety. In endogenous depression.
lorazepam given as an adjunct to antidepressant agents
appeared to lessen tension and improve the mood by
virtue of its sedative effect, but did not directly affect the
depression. Lorazepam was also effective in phobic states
with a strong anxiety component. In most cases dosage
adjustment was necessary, depending on the degree of
anxiety and tension and previous habituation to similar
anxiolytic and sedative-hypnotic agents. Alone or as con-
comitant therapy with antidepressant and other agents, the
usually effective dose range for lorazepam was 1 - 3 mg
and doses as high as 9 mg were without serious side-
effects. None of the patients in this series showed intoler-
ance to lorazepam.
In conclusion, findings from this study are in agreement
with those of other studies·· H which suggest that lorazepam
possesses pronounced anxiolytic and sedative-hypnotic
properties, is free from serious side-effects and is a useful
addition to treatment of neurotic disturbances which are
accompanied by anxiety. tension and insomnia.
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